4 research outputs found
<i>In vitro</i> neutralization of toxins from <i>C</i>. <i>difficile</i> clinical isolates by mAbs using xCELLigence<sup>®</sup> test.
<p><i>In vitro</i> neutralization of toxins from <i>C</i>. <i>difficile</i> clinical isolates by mAbs using xCELLigence<sup>®</sup> test.</p
Summary of humanized (IgG1/κ) anti-toxin mAbs and murine progenitor from which they were derived.
<p>Summary of humanized (IgG1/κ) anti-toxin mAbs and murine progenitor from which they were derived.</p
Survival after lethal rTcdA challenge in mice.
<p>Kaplan-Meier plot of survival following lethal challenge with rTcdA alone, or treatment with CANmAbA4 at either 250 μg or 50 μg dose in comparison to the CDA1 anti-TcdA and polyclonal (pAb anti-TcdA) control. Following lethal challenge, mice (n = 10) were monitored and sacrificed according to approved protocols. Statistical analysis (Log-rank Test) using GraphPad prism 5 indicated that all antibody treated groups had statistically significant higher survival rate compared to control group (rTcdA alone) (P<0.001). There is no significant difference in survival rate among antibody treated groups.</p
Survival after lethal rTcdB challenge in mice.
<p>Kaplan-Meier plot of survival following lethal challenge with rTcdB alone, or treatment with CANmAbB4 or CANmAbB1 at either 250 or 75 μg doses in comparison to the anti-TcdB rabbit polyclonal (pAb anti-TcdB) control. Following lethal challenge mice (n = 10) were monitored and sacrificed according to approved protocols. Statistical analysis (Log-rank Test) using GraphPad prism 5 indicated that all antibody treated groups had statistically significant higher survival rate compared to control group (rTcdA alone) (P<0.001). While CANmAbB4 treated animals (both 250 μg and 75 μg) showed statistically significant higher survival rate in comparison with CANmAbB1 (250 μg) (P<0.01).</p